Amendments to the Specification:

Please enter the accompanying paper copy of the sequence listing, pages 1-18, at the end of the application.

Please amend the paragraph beginning on page 3, line 15 as follows:

FIGS 1A-1D show levels of mRNA for TNFα (1A), MIP1α (1B), GFAP (1C) and IL1β (1C) measured in transgenic (closed symbols) and control (open symbols) mice at 2, 10, 12 and 18 months of age, where mRNA levels are normalized to GAPDH levels;

FIGS. 2A-2C show levels of mRNA for mHC IIα (2A), CD86 (2B), and MHC II Li (2C) measured in transgenic (closed symbols) and control (open symbols) mice at 2, 10, 12, and 18 months of age, where mRNA levels are normalized to GAPDH mRNA levels;

FIGS. 3A and 3B show a time course tracing of rat body temperatures before and after bilateral carotid occlusion (BCO), as indicated, in a rat where temperature readings (°C) were taken every five minutes (3A), and gross motor activity tracing based on activity readings measured in units/5 minutes (3B);

FIGS. 4A and 4B show a time course tracing of rat body temperatures before and after sham operation for BCO, as indicated, in a rat where temperature readings of (°C) were taken every five minutes (4A), and gross motor activity tracing based on activity readings measured in units/5 minutes (4B);

FIGS. 5A and 5B show levels of mRNA for MIPα (5A) and TNFα (5B) in BCO-operated mice (n=10), sham-operated mice (n=9), radiotransmitter-implanted mice (n=9) and untreated mice (n=6) 24 hours post reperfusion, where BCO-operated mice are indicated by open bars;

FIGS 6A-6D show levels of mRNA for inflammatory markers GFAP (6A) IL1β(6B) MHC IIα (6C) and CD86(6D) in individual BCO-operated mice receiving a 15 minute period of occlusion of blood flow (n=10), sham-operated mice receiving transmitter implant and

BCO surgery without occlusion of blood flow (n=9), radiotransmitter-implanted mice (n=9) and untreated mice (n=6) 24 hours post reperfusion, where BCO-operated mice are indicated by open bar; and

FIGS. 7A and 7B show induction of MHC II (7A) and GFAP (7B) on the left (4L) denervated side compared to the control right (4R) side after rat facial nerve axotomy (RFNA) where tissues from four animals were pooled for each analysis.

Please amend Table 3 on page 17 as follows:

//

//

Table 3
qtPCR primers and probes, inflammatory efficacy markers

assay	Genbank #	forward primer	reverse primer	probe
murine GAPDH		Name: MoGapdh251F Sequence: GGGAAGCCCATCACCATCTT (SEQ ID NO:1)	Name: MoGapdh363R Sequence: GCCTTCTCCATGGTGGTGAA (SEQ ID NO:2)	Name: MoGapdh272T Sequence: CAGGAGCGAGACCCCACTAACATCAAATG (SEQ ID NO:3)
murine GFAP		Name: mGFAP-420F Sequence: CTGGAGGTGGAGAGGGACAA (SEQ ID NO:4)	Name: mGFAP-489R Sequence: TGGTTTCATCTTGGAGCTTCTG (SEQ ID NO:5)	Name: mGFAP-443T Sequence: TGCACAGGACCTCGGCACCCT (SEQ ID NO:6)
murine MIP1α		Name: mMip1a128F Sequence: CAAGTCTTCTCAGCGCCATATG (SEQ ID NO:7)	Name: mMip1a229R Sequence: GGTTTCAAAATAGTCAACGATGAATTG (SEQ ID NO:8)	Name: mMip1a172T Sequence: CTGCTTCTCCTACAGCCGGAAGATTCCAC (SEQ ID NO:9)
murine TNF-α		Name: mTNFa-420F Sequence: CTGGAGGTGGAGAGGGACAA (SEQ ID NO:10)	Name: mTNFa–492R Sequence: GGTTGGTTTCATCTTGGAGCTT (SEQ ID NO:11)	Name: mTNFa-442T Sequence: TTGCACAGGACCTCGGCACCC (SEQ ID NO:12)
murine Il1-β		Name: mIL1B-2F Sequence: GCAGGGTTCGAGGCCTAATAG (SEQ ID NO:13)	Name: mIL1B–114R Sequence: GTGGCATTTCACAGTTGAGTTCA (SEQ ID NO:14)	Name: mIL1B-30T Sequence: TGGGATCCTCTCCAGCCAAGCTTCC (SEQ ID NO:15)
murine CD86		Name: mCD86 #2-250F Sequence: GGCCGCACGAGCTTTG (SEQ ID NO:16)	Name: mCD86 #2-321R Sequence: CGAGCCCATGTCCTTGATCT (SEQ ID NO:17)	Name: mCD86 #2-267T Sequence: CAGGAACAACTGGACTCTACGACTTCACAATG (SEQ ID NO:18)
murine MHCII li		Name: mMHC II(Ia),Li chain-418F Sequence: CGCGGGCGCCATAA (SEQ ID NO:19)	Name: mMHC II(Ia),li chain-479R Sequence: ACTCCCAGGCCAGAAGATAGG (SEQ ID NO:20)	Name: mMHC II(Ia),li chain-433TR Sequence: CTTCCATGTCCAGTGGCTCACTGCA (SEQ ID NO:21)
murine MHCIIα		Name: mMHC II(Ia),a chain-294F Sequence: CCACCCCAGCTACCAATGAG (SEQ ID NO:22)	Name: mMHC II(Ia),a chain-386R Sequence: CCACAAAGCAGATGAGGGTGTT (SEQ ID NO:23)	Name: mMHC II(Ia),a chain-335T Sequence: CCCAAGTCCCCTGTGCTGCTGG (SEQ ID NO:24)
rat GAPDH	M17701	Name: R.GAPDH-750F Sequence: TGCCAAGTATGATGACATCAAGAA (SEQ ID NO:25)	Name: R.GAPDH-820R Sequence: AGCCCAGGATGCCCTTTAGT (SEQ ID NO:26)	Name: R.GAPDH-781T Sequence: AAGCAGGCGGCCGAGGGC (SEQ ID NO:27)
rat GFAP	z48978	Name: R.GFAP-2099F Sequence: CTCAATGACCGCTTTGCTAGCT (SEQ ID NO:28)	Name: R.GFAP-2165R Sequence: CCAGCGCCTTGTTTTGCT (SEQ ID NO:29)	Name: R.GFAP-2122T Sequence: CATCGAGAAGGTCCGCTTCCTGGA (SEQ ID NO:30)
rat MHCII α	M29311	Name: R.MHC II a-196F Sequence: GGCACAGTCAAGGCTGAGAAT (SEQ ID NO:31)	Name: R.MHC II a-266R Sequence: TCGCGCTCCTGGAAGATG (SEQ ID NO:32)	Name: R.MHC II a-220T Sequence: AAGCTGGTCATCAATGGGAAACCCATC (SEQ ID NO:33)

Table 6

Marker	F. primer seq.	R. primer seq.	probe seq.
Osteopontin	15F: GATTTGCTTTTGCCTGTTTGG (SEQ ID NO:34)	81R: TGAGCTGCCAGAATCAGTCACT (SEQ ID NO:35)	38T: TTGCCTCCTCCCTCCCGGTGA (SEQ ID NO:36)
VitD3-24OHase	1164F:CCCAAGTGTGCCATTCACAAC (SEQ ID NO:37)	1236R:TCCTTTGGGTAGCGTGTATTCA (SEQ ID NO:38)	1186:CGGACCCTTGACAAGCCAACCGT (SEQ ID NO:39)
MCP-1	47F:GCTGGAGCATCCACGTGTT (SEQ ID NO:40)	142R:GCCTACTCATTGGGATCATCTTG (SEQ ID NO:41)	71T:AGCCAGATGCAGTTAACGCCCCACT (SEQ ID NO:42)
IL-10	#2-294F:AGAGAAGCATGGCCCAGAAAT (SEQ ID NO:43)	#2-365R:CGCATCCTGAGGGTCTTCA (SEQ ID NO:44)	#2-317T:CTTCTCACCCAGGGAATTCAAATGCTCCT (SEQ ID NO:45)
IL-12 p40, #1	662F:ACAGCACCAGCTTCTTCATCAG (SEQ ID NO:46)	734R:TTCAAAGGCTTCATCTGCAAGTT (SEQ ID NO:47)	687T:CATCATCAAACCAGACCCGCCCAA (SEQ ID NO:48)
#2	929F:ACATCTACCGAAGTCCAATGCA (SEQ ID NO:49)	1002R:CATGAGGAATTGTAATAGCGATCCT (SEQ ID NO:50)	952T:AGGCGGGAATGTCTGCGTGCA (SEQ ID NO:51)
IFN-gamma, #1	378F:CAGCAACAGCAAGGCGAAA (SEQ ID NO:52)	450R:CTGGACCTGTGGGTTGTTGAC (SEQ ID NO:53)	398T:AGGATGCATTCATGAGTATTGCCAAGTTTGA (SEQ ID NO:54)
#2	67F:ACAATGAACGCTACACACTGCAT (SEQ ID NO:55)	139R:CGTGGCAGTAACAGCCAGAA (SEQ ID NO:56)	91T:TTGGCTTTGCAGCTCTTCCTCATGG (SEQ ID NO:57)
CD3 epsilon	115F:GAGTTGACGTGCCCTCTAGACAG (SEQ ID NO:58)	193R:TATCATGCTTCTGAGGCAGCTC (SEQ ID NO:59)	140T: TGGCCATTTTTTTCCCATTTTAAGTTCTCGT (SEQ ID NO:60)
CD4, #1	359F:AGGTGGAGTTGTGGGTGTTCA (SEQ ID NO:61)	426R:CAGGCTCTGCCCTTGCAA (SEQ ID NO:62)	381T:AGTGACCTTCAGTCCGGGTACCAGCC (SEQ ID NO:63)
#2	388F:AGGAAAGAGGAGGTGGAGTTGTG (SEQ ID NO:64)	465R:CAGGCTCTGCCCTTGCAA (SEQ ID NO:65)	413T:TGTTCAAAGTGACCTTCAGTCCGGGTACC (SEQ ID NO:66)
IgG-1	134F: TGGAGGTGCACACAGCTCAG (SEQ ID NO:67)	195R: TGAGCGGAAAGTGCTGTTGA (SEQ ID NO:68)	155T: CTGCTCCTCCCGGGGTTGCG (SEQ ID NO:69)
Ig k (light chain)	151F:GGCGTCCTGAACAGTTGGA (SEQ ID NO:70)	219R:CGTGAGGGTGCTGCTCATG (SEQ ID NO:71)	171T:TGATCAGGACAGCAAAGACAGCACCTACA (SEQ ID NO:72)

Marker	Amplicon
Osteopontin	gatttgcttttgcctgtttggcattgcctcctccctcccggtgaaagtgactgattctggcagctca (SEQ ID NO:73)
VitD3-24OHase	cccaagtgtgccattcacaactcggacccttgacaagccaaccgttctgggtgaatacacgctacccaaagga (SEQ ID NO:74)
MCP-1	gctggagcatccacgtgttggctcagccagatgcagttaacgccccactcacctgctgctactcattcaccagcaagatgatcccaatgagtaggc (SEQ ID NO:75)
IL-10	agagaagcatggcccagaaatcaaggagcatttgaattccctgggtgagaagctgaagaccctcaggatgcg (SEQ ID NO:76)
IL-12 p40, #1	acagcaccagcttcttcatcagggacatcatcaaaccagacccgcccaagaacttgcagatgaagcctttgaa (SEQ ID NO:77)
#2	acatctaccgaagtccaatgcaaaggcgggaatgtctgcgtgcaagctcaggatcgctattacaattcctcatg (SEQ ID NO:78)
IFN-gamma, #1	cagcaacagcaaggcgaaaaaggatgcattcatgagtattgccaagtttgaggtcaacaacccacaggtccag (SEQ ID NO:79)

#2	acaatgaacgctacacactgcatcttggctttgcagctcttcctcatggctgtttctggctgttactgccacg (SEQ ID NO:80)
CD3 epsilon	gagttgacgtgccctctagacagtgacgagaacttaaaatgggaaaaaaatggccaagagctgcctcagaagcatgata (SEQ ID NO:81)
CD4, #1	aggtggagttgtgggtgttcaaagtgaccttcagtccgggtaccagcctg (SEQ ID NO:82)
#2	aggaaagaggaggtggagttgtgggtgttcaaagtgaccttcagtccgggtaccagcctgttgcaagggcagagcctg (SEQ ID NO:83)
IgG-1	tggaggtgcacacagctcagacgcaaccccgggaggagcagttcaacagcactttccgctca (SEQ ID NO:84)
Ig k (light chain)	ggcgtcctgaacagttggactgatcaggacagcaaagacagcacctacagcatgagcagcaccctcacg (SEQ ID NO:85)

//

//

//

//

//